Abstract
The Ig-CTF immunoassay was tested in serum, plasma and whole blood samples for healthy volunteers with normal glucose (n = 126), gestational pre-diabetics (n = 48), long term diabetics (n = 63) and in a population undergoing pre-diabetic assessment (n = 240). Patients with inflammation (n = 13), using immunosuppressants (n = 20), anti TNF alpha therapies (n = 8) or with breast cancer (n = 5), liver disease (n = 23), or pancreatic cancer (n = 10) were also assessed. The values for Ig-CTF were compared to Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) detected by OGTT results and HbA1c test result. The circulating Ig-CTF values are suppressed in diabetics and inflammation. Patients using anti- TNF α therapies (Remicade® Infliximab) exhibited suppressed Ig-CTF. The Ig-CTF values did not change following glucose administration or over 45 days without significant weight changes and the within patient variability was <10 %. The predictive value of Ig-CTF for an advanced diabetic disease to healthy control diabetes was a 92 % sensitivity and 93 % specificity. Ig-CTF was unable to resolve early diabetes from normals Ig-CTF did not meet any predictive value criteria. Only 10 % of earth diabetics and pre-diabetics had abnormally low Ig-CTF values.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brooks-Worrell B, Palmer JP (2011) Diabetes mellitus a continuous spectrum? Clin Chem 57(21):58–161
Catalano PM (2010) Obesity, insulin resistance and pregnancy outcome. Reproduction 140(3):365–371
DeFronzo RA et al (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237(3):E214–E223
Dickler HB (1973) Lymphocyte binding of aggregated IgG and surface Ig staining in chronic lymphocytic leukaemia. Clin Exp Immunol 14:97–106
Dods RF, Bolmey C (1979) Glycosylated hemoglobin assay and oral glucose tolerance test compared for detection of diabetes mellitus. Clin Chem 25(5):764–768
Hamad OA et al (2010) Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol 184(5):2686–2692
Hinton PR et al (2006) An engineered human IgG1 antibody with longer serum half life. J Immunol 176:346–356
Katsuki A (2001) Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 24:362–365
Lee HW et al (2011) Comparison between surrogate indexes of insulin sensitivity/resistance glucose clamps in rhesus monkeys. Endocrinology 152(2):414–423
Lopes-Virella MF et al (2008) Diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort study group. Diabetes Care 31(10):2006–2012
Muniyappa R et al (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294:E15–E26
Sacks DB et al; National Academy of Clinical Biochemistry; Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry (2011) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 34(6):e61–e99
Sathananthan A et al (2012) A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. Clin Endocrinol (Oxf) 76(2):212–219
Tabák AG et al (2012) Prediabetes: a high-risk state for diabetes development. Lancet 379(9833):2279–2290
Tieu J et al (2010) Screening and subsequent management for gestational diabetes for improving maternal and infant health. Cochrane Database Syst Rev 7:CD007222
Tura A et al (2001) Insulin and C-peptide secretion and kinetics in OGTT humans: direct and model-based measurements during. Am J Physiol Endocrinol Metab 281:E966–E974
Worth RG et al (2006) Platelet Fc gamma RIIA binds and internalizes IgG-containing complexes. Exp Hematol 34(11):1490–1495
Acknowledgements
We would like to acknowledge the samples collected by Sandra D. Pottorf, CLS, ASCP (Methodist Medical Center of Illinois, Chicago IL); the samples removed from storage by Jessica Cray and Linda Sanders (Mayo Clinic Rochester, MN); the samples provided by Randie R. Little, PhD (Diabetes Diagnostic Laboratory, University of Missouri School of Medicine, Columbia MS); and the samples procurement help from Denise Cervelli of (Siemens Healthcare Diagnostic Newark DE).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Supplements
Supplements
-
ELISA Method for Ig-CTF assay
-
ELISA Method for free CTF assay
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Vella, A., Pugia, M. (2015). C-Terminal Fragment of Adiponectin Receptor Clinical Correlations. In: Pugia, M. (eds) Inflammatory Pathways in Diabetes. Progress in Inflammation Research. Springer, Cham. https://doi.org/10.1007/978-3-319-21927-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-21927-1_6
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21926-4
Online ISBN: 978-3-319-21927-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)